Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aclaris Therapeutics Inc ACRS

Healthcare
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on... see more

Recent & Breaking News (NDAQ:ACRS)

Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa

GlobeNewswire March 6, 2023

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

GlobeNewswire February 23, 2023

Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference

GlobeNewswire February 9, 2023

Aclaris Therapeutics Provides 2023 Outlook

GlobeNewswire January 6, 2023

Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China

GlobeNewswire November 29, 2022

Aclaris Therapeutics Announces Key Leadership Transitions

GlobeNewswire November 22, 2022

Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences

GlobeNewswire November 10, 2022

Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

GlobeNewswire November 8, 2022

Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations

GlobeNewswire September 27, 2022

Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire August 30, 2022

Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata

GlobeNewswire August 25, 2022

Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

GlobeNewswire August 3, 2022

Aclaris Therapeutics Expands Leadership Team

GlobeNewswire August 1, 2022

Aclaris Therapeutics Expands Leadership Team

GlobeNewswire June 27, 2022

Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference

GlobeNewswire June 1, 2022

Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

GlobeNewswire May 16, 2022

Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

GlobeNewswire May 10, 2022

Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium

GlobeNewswire May 3, 2022

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

GlobeNewswire February 24, 2022

Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference

GlobeNewswire February 2, 2022